YY1 and neoplasm: YY1 acts as a downstream effector in the NF-κB/SNAIL pathway, repressing RKIP expression to promote tumor EMT and treatment resistance, while NO donors downregulate YY1 to restore RKIP activity and reverse drug resistance (Figure 6) [145,146].